MedTrace Logo

Effect of Consumption of a Novel Functional Yogurt on Blood Biomarkers of Healthy Participants

NCT05612243 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2022-12-06

No results posted yet for this study

Summary

The purpose of the study is to assess the effect of a dietary intervention that includes the consumption of a novel functional yogurt (enriched with probiotics and polyphenols) on the blood biomarkers of healthy participants.

Conditions

  • Healthy

Interventions

OTHER

Consumption of a meal with yogurt enriched with probiotics immobilized on oat flakes and polyphenols

Participants will consume a meal including 200g of yogurt enriched with Lacticaseibacillus rhamnosus probiotics (3\*10\^9 cfu/g) immobilized on oat flakes (1g) and polyphenol-rich lyophilized extract (250mg) of Cistus Albidus (77,3 mg GAE/g), as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of functional yogurt on postprandial glycemia and lipemia

OTHER

Consumption of a meal with yogurt enriched with probiotics immobilized on oat flakes

Participants will consume a meal including 200g of yogurt with Lacticaseibacillus rhamnosus probiotics (3\*10\^9 cfu/g) immobilized on oat flakes (1g), as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of probiotic-enriched yogurt on postprandial glycemia and lipemia.

OTHER

Consumption of a meal with plain Yogurt with oat flakes

Participants will consume a meal including 200g of plain yogurt containing 1g of oat flakes, as a placebo, as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of probiotic-enriched yogurt on postprandial glycemia and lipemia.

Sponsors & Collaborators

  • Democritus University of Thrace

    collaborator OTHER

  • University of Ioannina

    collaborator OTHER

  • ANTONIOS KOUTELIDAKIS

    lead OTHER

Principal Investigators

  • Antonios E. Koutelidakis · University of the Aegean

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-17
Primary Completion
2022-12-10
Completion
2022-12-16

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05612243 on ClinicalTrials.gov